SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
ABT Analysis & Videos »
ABT: Bull or Bear?
Serious Money: Five more high yield, safe, diversified stocks -- Part 2
ABT
|
|
|
+11.74%
in
117 days
Filed under: Good news, Market matters, Getting started, Diageo plc (DEO), Abbott Laboratories (ABT), Automatic Data Proc (ADP), ConocoPhillips (COP), Duke Energy (DUK), Serious Money, Oil, Stocks to Buy, Financial Crisis  The market may be entering a more volatile period or it may just go sideways for a while. The last few weeks the market has been down. Maybe it is because the rapid rise mid-March through mid-June is forcing people to stop and take a breadth, or perhaps it is because investors are having second thoughts about whether the "green shoots" Ben Bernanke spoke of in regards to a ...
|
FDA Calendar Updates: ABT, AFFY, AZN, LLY, MELA, PFE, VPHM
ABT
|
|
|
+15.27%
in
157 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following additional categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pen...
|
Abbott (ABT): An 'income machine'
ABT
+5.76%
in
156 days
(closed on 09/17/09)
Filed under: Newsletters, Abbott Laboratories (ABT), Stocks to Buy  "Abbott Laboratories (NYSE: ABT) is continuing its long record of rewarding shareholders," notes Alex Kolb In Zacks Elite, pointing to its 341st consecutive quarter of dividends since 1924.
"Abbott is a global, broad-based health care company that develops, manufactures and markets pharmaceuticals and medical products, including nutritionals, devices and diagnostics. "The company employs more than 68,000 people and markets its products in more than 130 countries. <>"The company recently released new data, showing that a combinatio...
|
FDA and Clinical Trial Calendar Updates
ABT
|
|
|
-1.95%
in
71 days
(closed on 06/04/09)
FDA and Clinical Trial Calendar Updates <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 106 entries through 3/25/09. The FDA Calendar includes the fo...
|
New Index of Highly Defensive Market Cap Leaders
ABT
|
|
|
-16.34%
in
28 days
(closed on 03/25/09)
The ETF Innovators Highly Defensive Index contains 40 market cap leading companies which are based in either North America or Europe from the defensive industry groups (A-K) specified below. www.BioMedReports.com - Mike Havrilla (A) Mass Merchant Discount Retailer (1): Wal-Mart (WMT) <> <> (B) Consumer Staples (12): Coca-Cola (KO), Colgate-Palmolive (CL), Diageo (DEO), General Mills (GIS), Danone (GDNNY), Kraft Foods (KFT), Nestle (NSRGY), PepsiCo (PEP), Philip Morris International (PM), Procter & Gamble (PG), Reckitt Benckiser (RBGPF), Unilever (UN) <><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />...
|
Abbott (ABT): Contrarian sees healthy gains
ABT
-20.39%
in
74 days
(closed on 04/14/09)
Filed under: Newsletters, Abbott Laboratories (ABT), Stocks to Buy <!----> "The company has been around for more than 120 years. It currently operates in more than 130 countries, selling hundreds of products, including Ultane (an inhaled anesthetic), the anti-infective Biaxin XL, and TriCor and Niaspan to manage cholesterol. <>"However, Abbott's biggest growth driver is Humira, a blockbuster drug that targets ...
|
A More Focused Highly Defensive Index
ABT
|
|
|
+6.68%
in
83 days
(closed on 02/25/09)
<> 
The accompanying table [click to enlarge] includes an updated version of the ETF Innovators [ETFI] ETFI Highly Defensive PerformIdex of 36 companies based in the U.S., Canada, and Europe with market caps over $10B, which are the leaders by market cap in their defensive industry groups. This update includes a 10% reduction in the number of companies with an equal distribution of 12 each from consumer staples and healthcare, with the remaining 12 companies chosen from a variety of defensive industry groups.
(A) Mass Merch...
|
Stock Picks for Healthy Returns
ABT
|
|
|
-0.45%
in
8 days
(closed on 12/03/08)
<> Abbott Labs (ABT) is a consistent performer with diversified healthcare operations, including pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents. ABT is back to the lower end of its trading range near 50 bucks, presenting an excellent entry point with a 2.8% dividend yield and forward PE of about 14X.
Celgene (CELG) is also trading at the low end of its trading range around 50 bucks as a large-cap growth stock focused on cancer biotech products and research with an estimated PEG ratio below one.
...
|
A New Global Healthcare Composite Index
ABT
|
|
|
-1.06%
in
2 days
(closed on 11/25/08)
<> 
The accompanying table [click to enlarge or download] presents the top five rated companies with market caps of at least $250M from each of the 10 new healthcare indexes developed by ETF Innovators [ETFI] from a database of about 500 companies worldwide. The ETFI Global Healthcare Sector PerformIdex consists of 50 top rated companies on an equal weight basis from each of the 10 new healthcare indexes as an alternative strategy to existing health composite ETFs with highly correlated returns and over-weight exposure to th...
|
ETFI Health Innovators Index: Does R&D Lead to Higher Stock Prices?
ABT
|
|
|
-4.98%
in
11 days
(closed on 11/23/08)
<> 
<> The accompanying table includes statistics and the top five rated companies in the ETFI Global Health Innovators Index of companies with market caps over $100M which received FDA approval in the trailing 12-month period for either an original new drug or medical device product. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for existing produc...
|
FDA Action Heats Up Before Year-End
ABT
|
|
|
-2.98%
in
18 days
(closed on 11/08/08)
<> 
The accompanying table presents an updated calendar of expected FDA decision dates and advisory committee [FDAC] meetings expected to impact the price of underlying biotech and pharma stocks. Genzyme (GENZ) faces a FDAC tomorrow (10/21) for its pending BLA for Myozyme manufactured at the 2,000L bioreactor scale. Also, Discovery Labs (DSCO) submitted its complete response to the FDA last Friday to address an approvable ruling for Surfaxin back in May and insiders continue to buy the stock. DSCO expects the FDA to rule on Surfaxin...
|
People Bullish on ABT
People Bearish on ABT
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Be the first to start a discussion and earn 2 points.
More Resources
|
About Abbott Laboratories
- Answers.com
